Stay updated on BPN14770 in Fragile X Syndrome Clinical Trial
Sign up to get notified when there's something new on the BPN14770 in Fragile X Syndrome Clinical Trial page.

Latest updates to the BPN14770 in Fragile X Syndrome Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous funding notice and v3.4.1 revision, which are administrative site updates rather than changes to study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check21 days agoChange DetectedA government funding notice banner is now displayed on the page and the site version tag updated to v3.4.1. No core study content or critical page elements were altered.SummaryDifference0.7%

- Check28 days agoChange DetectedShow glossary option added and color-coded highlights for additions and deletions in the history view. The revision label updated to v3.4.0, replacing v3.3.4.SummaryDifference1.0%

- Check42 days agoChange DetectedA new site revision label v3.3.4 is added and the previous label v3.3.3 is removed from the record history. This reflects internal UI versioning and does not modify trial details, data, or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.3.3 was added to the history; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check91 days agoChange DetectedRevision history now shows an addition of v3.3.2 and a deletion of v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to BPN14770 in Fragile X Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BPN14770 in Fragile X Syndrome Clinical Trial page.